Photothermal-sensitive biomimetic liposomes coated with DOX and IR820 for chemo-photothermal-photodynamic therapy of cancer in lung cancer cells
In this study,doxorubicin(DOX)was used as the model drug,new indocyanine green(IR820)as the photosensitizer,and temperature sensitive liposomes(TSL)as the carrier.H460-NCI photoheat-sensitive liposomes coated with cell membrane of human cell lung cancer(DOX-IR820-TSL@CCM)for highly effective multi-pathway tumor targeting in chemical-photothermal therapy and photodynamic therapy.DOX-IR820-TSL was prepared by reverse evaporation,cancer cell membrane(CCM)was prepared by lysis,crushing and centrifugation,and DOX-IR820-TSL@CCM was prepared by nanomembrane extrusion.The drug-loading conditions of DOX-IR820-TSL were finally determined:the ratio of organic phase to aqueous phase was 4.02,the dosage of dipalmitoyl-sn-glycero-3-phosphocholine(DPPC)was 10.04 mg,and the lipid ratio was 0.12,and the significant phase transition temperature(Tm)of DOX-IR820-TSL was 43.05 ℃.The average particle size of DOX-IR820-TSL@CCM was 153.4 nm,the PDI was 0.279,and the zeta potential was-26.2 mV.The transmission electron microscope(TEM)image shows a homogeneous spherical structure and a translucent film layer.Under near-infrared irradiation,the drug release rate reaches 63.98％,which has adjustable photothermal conversion capacity and the ability to generate reactive oxygen species.Through SDS-PAGE electrophoresis,Western blot,cytotoxicity experiments and cell uptake experiments,it was proved that the design of cell membrane coating can well retain CD47,N-cadherin,CD44,CD326 and other related functional proteins,so that DOX-IR820-TSL@CCM has good immune evasion,homologous adhesion and homologous targeting.In this paper,DOX-IR820-TSL@CCM with camouflage properties and tumor targeting properties were successfully prepared,which can be used as a promising synergistic therapeutic diagnostic platform for future lung cancer treatment.All animal research programs have been approved by the Animal Ethics Committee of Heilongjiang University of Chinese Medicine(number:2022121011).
NETL
NSTL
万方数据
